In 2019, Bloomberg Law reported that the FDA had cited BioTE for failing to report over 4,000 adverse events linked to its hormonal medicines. An FDA investigation in 2018 also associated compounded ...

As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT ...